Stockreport

Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates [Yahoo! Finance]

Passage Bio, Inc.  (PASG) 
PDF FDA feedback from recent Type C meeting indicated a randomized controlled registrational trial will be required for PBFT02 in FTD-GRN The Company initiated a strategi [Read more]